159 related articles for article (PubMed ID: 38156603)
41. Investigating the Efficacy of HPV Vaccines in Preventing Cervical Cancer from 2006 to 2018 in the US: A SEER Data Set Analysis.
Mattis A; Beydoun H; Dobrydneva Y; Ganjoo R
Rev Recent Clin Trials; 2023; 18(3):214-222. PubMed ID: 37046192
[TBL] [Abstract][Full Text] [Related]
42. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
43. Prevention of Cervical Cancer in Low-Resource African Settings.
Mulongo M; Chibwesha CJ
Obstet Gynecol Clin North Am; 2022 Dec; 49(4):771-781. PubMed ID: 36328679
[TBL] [Abstract][Full Text] [Related]
44. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
45. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer].
Friedek DA; Ekiel AM; Martirosian G
Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966
[TBL] [Abstract][Full Text] [Related]
46. Healers in a non-traditional role; a focus group study of Sangoma's knowledge of and attitudes to cervical cancer prevention and screening in Johannesburg, South Africa.
Nelson JA; Francis SA; Liverpool J; Soogun S; Mofammere N
Sex Reprod Healthc; 2010 Nov; 1(4):195-6. PubMed ID: 21122621
[TBL] [Abstract][Full Text] [Related]
47. MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China.
Deng S; Welby S; Liu Z; Yang Y; Meng R; Sun Y; Yang J; Liu G; He Y; Jiang N; Wu Z; Liu K; Rosillon D; Cohet C; Borys D; Zhan S
Hum Vaccin Immunother; 2023 Aug; 19(2):2257989. PubMed ID: 37813849
[TBL] [Abstract][Full Text] [Related]
48. Modelling the impact of prevention strategies on cervical cancer incidence in South Africa.
van Schalkwyk C; Moodley J; Welte A; Johnson LF
Int J Cancer; 2021 Oct; 149(8):1564-1575. PubMed ID: 34164807
[TBL] [Abstract][Full Text] [Related]
49. Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe.
Gaete S; Auguste A; Bhakkan B; Peruvien J; Herrmann-Storck C; Socrier Y; Diedhiou A; Deloumeaux J
BMC Cancer; 2021 Mar; 21(1):281. PubMed ID: 33726684
[TBL] [Abstract][Full Text] [Related]
50. Acceptability of human papillomavirus vaccine: a survey among master of business administration students in KwaZulu-Natal, South Africa.
Hoque ME; Van Hal G
Biomed Res Int; 2014; 2014():257807. PubMed ID: 25162003
[TBL] [Abstract][Full Text] [Related]
51. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
52. What school nurses need to know about cervical cancer, HPV, and the new vaccine.
Ehrhardt J
J Sch Nurs; 2007 Dec; 23(6):310-4. PubMed ID: 18052515
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?
Mandic A; Vujkov T
Ann Oncol; 2004 Feb; 15(2):197-200. PubMed ID: 14760108
[TBL] [Abstract][Full Text] [Related]
54. Examining attitudes and knowledge about HPV and cervical cancer risk among female clinic attendees in Johannesburg, South Africa.
Francis SA; Nelson J; Liverpool J; Soogun S; Mofammere N; Thorpe RJ
Vaccine; 2010 Nov; 28(50):8026-32. PubMed ID: 20887829
[TBL] [Abstract][Full Text] [Related]
55. Preparing for HPV vaccination in South Africa: key challenges and opinions.
Harries J; Moodley J; Barone MA; Mall S; Sinanovic E
Vaccine; 2009 Jan; 27(1):38-44. PubMed ID: 18977271
[TBL] [Abstract][Full Text] [Related]
56. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
57. Human papillomavirus vaccination and cervical cancer risk.
Rahangdale L; Mungo C; O'Connor S; Chibwesha CJ; Brewer NT
BMJ; 2022 Dec; 379():e070115. PubMed ID: 36521855
[TBL] [Abstract][Full Text] [Related]
58. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
59. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
60. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
